Show simple item record

dc.contributor.authorLiu, Shiqin
dc.contributor.authorShen, Michelle
dc.contributor.authorHsu, En-Chi
dc.contributor.authorZhang, Chiyuan Amy
dc.contributor.authorGarcia-Marques, Fernando
dc.contributor.authorNolley, Rosalie
dc.contributor.authorKoul, Kashyap
dc.contributor.authorRice, Meghan A
dc.contributor.authorAslan, Merve
dc.contributor.authorPitteri, Sharon J
dc.contributor.authorMassie, Charlie
dc.contributor.authorGeorge, Anne
dc.contributor.authorBrooks, James D
dc.contributor.authorGnanapragasam, Vincent
dc.contributor.authorStoyanova, Tanya
dc.date.accessioned2021-12-24T14:39:10Z
dc.date.available2021-12-24T14:39:10Z
dc.date.issued2021-03
dc.date.submitted2020-09-15
dc.identifier.issn0007-0920
dc.identifier.others41416-020-01200-0
dc.identifier.other1200
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/331823
dc.description.abstractDistinguishing clinically significant from indolent prostate cancer (PC) is a major clinical challenge. We utilised targeted protein biomarker discovery approach to identify biomarkers specific for pro-metastatic PC. Serum samples from the cancer-free group; Cambridge Prognostic Group 1 (CPG1, low risk); CPG5 (high risk) and metastatic disease were analysed using Olink Proteomics panels. Tissue validation was performed by immunohistochemistry in a radical prostatectomy cohort (n = 234). We discovered that nine proteins (pleiotrophin (PTN), MK, PVRL4, EPHA2, TFPI-2, hK11, SYND1, ANGPT2, and hK14) were elevated in metastatic PC patients when compared to other groups. PTN levels were increased in serum from men with CPG5 compared to benign and CPG1. High tissue PTN level was an independent predictor of biochemical recurrence and metastatic progression in low- and intermediate-grade disease. These findings suggest that PTN may represent a novel biomarker for the presence of poor prognosis local disease with the potential to metastasise warranting further investigation.
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectBrief Communication
dc.subject/631/67/589/466
dc.subject/631/67/2322
dc.subjectbrief-communication
dc.titleDiscovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
dc.typeArticle
dc.date.updated2021-12-24T14:39:10Z
prism.endingPage900
prism.issueIdentifier5
prism.publicationNameBr J Cancer
prism.startingPage896
prism.volume124
dc.identifier.doi10.17863/CAM.79272
dcterms.dateAccepted2020-11-12
rioxxterms.versionofrecord10.1038/s41416-020-01200-0
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidPitteri, Sharon J [0000-0002-3119-873X]
dc.contributor.orcidGnanapragasam, Vincent [0000-0003-4722-4207]
dc.contributor.orcidStoyanova, Tanya [0000-0003-0119-9747]
dc.identifier.eissn1532-1827
cam.issuedOnline2020-12-08


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record